By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics has priced its public offering of nearly 7.1 million shares of common stock at $4.25 per share.

The Carlsbad, Calif.-based molecular diagnostics firm said that it expects net proceeds from the offering to be roughly $27.6 million. If the underwriters exercise the over-allotment option of nearly 1.1 million shares, the firm's net proceeds will be approximately $31.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.